Biomarin Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. I'm pleased to have BioMarin here with us this afternoon. And with us, we have J.J. Bienaimé, Chairman and CEO; Hank Fuchs, President, Worldwide Research & Development; and Brian Mueller, Acting CFO.
And with that, I'll turn it over to you, J.J., in the case that you want to make some opening remarks here.
©,-&
So thank you, Salveen. We are very happy to participate in your June conference for the seventh year in a row, even if we cannot talk in person. So it is no coincidence that BioMarin is at a significant inflection point in 2020. We have been growing the company for many years, honing our R&D platform, advancing our manufacturing capabilities, expanding our global commercial footprint and working with the health authorities around the world to develop essential medicine
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
